These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19300899)

  • 1. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract]   [Full Text] [Related]  

  • 2. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
    Erdmann E; Spanheimer R; Charbonnel B;
    J Diabetes; 2010 Sep; 2(3):212-20. PubMed ID: 20923486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes mellitus and heart failure.
    Choy CK; Rodgers JE; Nappi JM; Haines ST
    Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
    Sillars B; Davis WA; Hirsch IB; Davis TM
    Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
    Walker AM; Koro CE; Landon J
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA; Eurich DT; Majumdar SR; Johnson JA
    Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin use and mortality among patients with diabetes and atherothrombosis.
    Roussel R; Travert F; Pasquet B; Wilson PW; Smith SC; Goto S; Ravaud P; Marre M; Porath A; Bhatt DL; Steg PG;
    Arch Intern Med; 2010 Nov; 170(21):1892-9. PubMed ID: 21098347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetes mellitus and heart failure: epidemiology and therapy].
    Pfister R; Erdmann E
    Herz; 2008 Apr; 33(3):178-83. PubMed ID: 18568311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin use in decompensated heart failure.
    Boyd A; Nawarskas J
    Cardiol Rev; 2008; 16(5):269-72. PubMed ID: 18708828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering therapy after myocardial infarction: more questions than answers.
    Radke PW; Schunkert H
    Eur Heart J; 2008 Jan; 29(2):141-3. PubMed ID: 18199566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
    Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter by Eller et al regarding article, "Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland".
    Eller K; Tancevski I; Eller P
    Circulation; 2010 Apr; 121(14):e377. PubMed ID: 20385959
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of heart failure in patients with diabetes: clinical update.
    Bell DS
    Ethn Dis; 2002; 12(1):S1-12-8. PubMed ID: 11915848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.
    Pfister R; Cairns R; Erdmann E; Schneider CA
    Int J Cardiol; 2013 Jan; 162(2):112-6. PubMed ID: 21636144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.